logo-loader

Golden Tag discovers new zone of epithermal mineralization at its San Diego silver project in Mexico

Published: 12:25 27 May 2021 EDT

Golden Tag Resources Ltd. -
The San Diego property is among the largest undeveloped silver assets in Mexico and is located within the prolific Velardeña Mining District

Golden Tag Resources Ltd (CVE:GOG) (OTCQB:GTAGF) revealed a new zone of epithermal mineralization on its San Diego project in Mexico.

Drill hole 21-57 intersected the new zone, with results coming in as high as 892.25 grams per ton silver equivalent (AgEq) over 10 metres and 115.33 g/t AgEq over 5.54 metres.

Toronto-based Golden Tag said that two previously unreported zones of mineralization in a historic drill hole may be related to the newly-discovered mineralization in hole 21-57. The historic hole was drilled around 10 metres east of 21-57 and intersected 213.85 g/t AgEq over 2 metres, while another hole intersected 404.29 g/t AgEq over 3.75 metres nearly 55 metres north-northeast of 21-57.

READ: Golden Tag Resources reveals high-grade silver results from its San Diego project in Mexico

Epithermal mineralization at San Diego differs from the more typically seen skarn mineralization on the project because the gold and silver grades are “significantly higher,” Golden Tag said in a statement.

"We were pleasantly surprised to have discovered this new mineralization, located at the top of hole 21-57 approximately 500 metres above the planned target area,” CEO Greg McKenzie told investors.

“This is a significant discovery because it opens up the potential for epithermal type mineralization on the San Diego Project, above and beyond the broad skarn mineralization typically encountered. Our next phase of drilling will attempt to follow up and expand upon this discovery.”

The San Diego property is among the largest undeveloped silver assets in Mexico and is located within the prolific Velardeña Mining District. Golden Tag owns a 100% interest in the project, subject to a 2% NSR.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 26 minutes ago